Improved tumor targeting by combined use of two antitenascin antibodies

Fiorella Petronzelli, Angela Pelliccia, Anna Maria Anastasi, Valeria D'Alessio, Claudio Albertoni, Antonio Rosi, Barbara Leoni, Clara De Angelis, Giovanni Paganelli, Giovanna Palombo, Maria Dani, Paolo Carminati, Rita De Santis

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: In the pretargeted antibody-guided radioimmunotherapy (PAGRIT) system, the combined use of two different antibodies directed against the same tumor antigen could represent a valid approach for improving tumor targeting and therapeutic efficacy. We developed a novel monoclonal antitenascin antibody, ST2485, and studied its biochemical and functional properties by in vitro and in vivo assays. We then investigated the first of the three-step therapy combining ST2485 with another antitenascin antibody, ST2146, previously described, to increase accumulation of biotinylated antibodies at the tumor site. Experimental Design: Studies of immunoreactivity, affinity, immunohistochemistry, and biodistribution in xenograft model were carried out on ST2485. Analysis of the ST2485 and ST2146 combination was preliminary carried out by ELISA and BiaCore tests and then by in vivo distribution studies after administration of the radiolabeled biotinylated antibodies, followed by a chase with avidin as clearing agent. Results: ST2485 was found to be a suitable antibody for therapeutic applications. Indeed, for its behavior in all tests, it was comparable with ST2146 and better than BC2, an antibody already used for clinical trials. The additivity of ST2146 and ST2485 in tenascin C binding, shown by in vitro tests, was confirmed by biodistribution studies in a xenograft model where tumor localization of the antibodies was near the sum of each antibody alone, with a tumor-to-blood ratio higher than 24. Conclusion: The results reported in this study suggest that a monoclonal antitenascin antibody mixture can improve tumor targeting. This strategy could represent progress for therapeutic approaches such as PAGRIT.

Original languageEnglish
JournalClinical Cancer Research
Volume11
Issue number19 II
DOIs
Publication statusPublished - Oct 1 2005

Fingerprint

Antibodies
Neoplasms
Neoplasm Antibodies
Radioimmunotherapy
Heterografts
Monoclonal Antibodies
Tenascin
Avidin
Neoplasm Antigens
Therapeutics
Research Design
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Clinical Trials
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Petronzelli, F., Pelliccia, A., Anastasi, A. M., D'Alessio, V., Albertoni, C., Rosi, A., ... De Santis, R. (2005). Improved tumor targeting by combined use of two antitenascin antibodies. Clinical Cancer Research, 11(19 II). https://doi.org/10.1158/1078-0432.CCR-1004-0007

Improved tumor targeting by combined use of two antitenascin antibodies. / Petronzelli, Fiorella; Pelliccia, Angela; Anastasi, Anna Maria; D'Alessio, Valeria; Albertoni, Claudio; Rosi, Antonio; Leoni, Barbara; De Angelis, Clara; Paganelli, Giovanni; Palombo, Giovanna; Dani, Maria; Carminati, Paolo; De Santis, Rita.

In: Clinical Cancer Research, Vol. 11, No. 19 II, 01.10.2005.

Research output: Contribution to journalArticle

Petronzelli, F, Pelliccia, A, Anastasi, AM, D'Alessio, V, Albertoni, C, Rosi, A, Leoni, B, De Angelis, C, Paganelli, G, Palombo, G, Dani, M, Carminati, P & De Santis, R 2005, 'Improved tumor targeting by combined use of two antitenascin antibodies', Clinical Cancer Research, vol. 11, no. 19 II. https://doi.org/10.1158/1078-0432.CCR-1004-0007
Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A et al. Improved tumor targeting by combined use of two antitenascin antibodies. Clinical Cancer Research. 2005 Oct 1;11(19 II). https://doi.org/10.1158/1078-0432.CCR-1004-0007
Petronzelli, Fiorella ; Pelliccia, Angela ; Anastasi, Anna Maria ; D'Alessio, Valeria ; Albertoni, Claudio ; Rosi, Antonio ; Leoni, Barbara ; De Angelis, Clara ; Paganelli, Giovanni ; Palombo, Giovanna ; Dani, Maria ; Carminati, Paolo ; De Santis, Rita. / Improved tumor targeting by combined use of two antitenascin antibodies. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 19 II.
@article{13dbfd844a1a49f6b7142550e23156a6,
title = "Improved tumor targeting by combined use of two antitenascin antibodies",
abstract = "Purpose: In the pretargeted antibody-guided radioimmunotherapy (PAGRIT) system, the combined use of two different antibodies directed against the same tumor antigen could represent a valid approach for improving tumor targeting and therapeutic efficacy. We developed a novel monoclonal antitenascin antibody, ST2485, and studied its biochemical and functional properties by in vitro and in vivo assays. We then investigated the first of the three-step therapy combining ST2485 with another antitenascin antibody, ST2146, previously described, to increase accumulation of biotinylated antibodies at the tumor site. Experimental Design: Studies of immunoreactivity, affinity, immunohistochemistry, and biodistribution in xenograft model were carried out on ST2485. Analysis of the ST2485 and ST2146 combination was preliminary carried out by ELISA and BiaCore tests and then by in vivo distribution studies after administration of the radiolabeled biotinylated antibodies, followed by a chase with avidin as clearing agent. Results: ST2485 was found to be a suitable antibody for therapeutic applications. Indeed, for its behavior in all tests, it was comparable with ST2146 and better than BC2, an antibody already used for clinical trials. The additivity of ST2146 and ST2485 in tenascin C binding, shown by in vitro tests, was confirmed by biodistribution studies in a xenograft model where tumor localization of the antibodies was near the sum of each antibody alone, with a tumor-to-blood ratio higher than 24. Conclusion: The results reported in this study suggest that a monoclonal antitenascin antibody mixture can improve tumor targeting. This strategy could represent progress for therapeutic approaches such as PAGRIT.",
author = "Fiorella Petronzelli and Angela Pelliccia and Anastasi, {Anna Maria} and Valeria D'Alessio and Claudio Albertoni and Antonio Rosi and Barbara Leoni and {De Angelis}, Clara and Giovanni Paganelli and Giovanna Palombo and Maria Dani and Paolo Carminati and {De Santis}, Rita",
year = "2005",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-1004-0007",
language = "English",
volume = "11",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19 II",

}

TY - JOUR

T1 - Improved tumor targeting by combined use of two antitenascin antibodies

AU - Petronzelli, Fiorella

AU - Pelliccia, Angela

AU - Anastasi, Anna Maria

AU - D'Alessio, Valeria

AU - Albertoni, Claudio

AU - Rosi, Antonio

AU - Leoni, Barbara

AU - De Angelis, Clara

AU - Paganelli, Giovanni

AU - Palombo, Giovanna

AU - Dani, Maria

AU - Carminati, Paolo

AU - De Santis, Rita

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Purpose: In the pretargeted antibody-guided radioimmunotherapy (PAGRIT) system, the combined use of two different antibodies directed against the same tumor antigen could represent a valid approach for improving tumor targeting and therapeutic efficacy. We developed a novel monoclonal antitenascin antibody, ST2485, and studied its biochemical and functional properties by in vitro and in vivo assays. We then investigated the first of the three-step therapy combining ST2485 with another antitenascin antibody, ST2146, previously described, to increase accumulation of biotinylated antibodies at the tumor site. Experimental Design: Studies of immunoreactivity, affinity, immunohistochemistry, and biodistribution in xenograft model were carried out on ST2485. Analysis of the ST2485 and ST2146 combination was preliminary carried out by ELISA and BiaCore tests and then by in vivo distribution studies after administration of the radiolabeled biotinylated antibodies, followed by a chase with avidin as clearing agent. Results: ST2485 was found to be a suitable antibody for therapeutic applications. Indeed, for its behavior in all tests, it was comparable with ST2146 and better than BC2, an antibody already used for clinical trials. The additivity of ST2146 and ST2485 in tenascin C binding, shown by in vitro tests, was confirmed by biodistribution studies in a xenograft model where tumor localization of the antibodies was near the sum of each antibody alone, with a tumor-to-blood ratio higher than 24. Conclusion: The results reported in this study suggest that a monoclonal antitenascin antibody mixture can improve tumor targeting. This strategy could represent progress for therapeutic approaches such as PAGRIT.

AB - Purpose: In the pretargeted antibody-guided radioimmunotherapy (PAGRIT) system, the combined use of two different antibodies directed against the same tumor antigen could represent a valid approach for improving tumor targeting and therapeutic efficacy. We developed a novel monoclonal antitenascin antibody, ST2485, and studied its biochemical and functional properties by in vitro and in vivo assays. We then investigated the first of the three-step therapy combining ST2485 with another antitenascin antibody, ST2146, previously described, to increase accumulation of biotinylated antibodies at the tumor site. Experimental Design: Studies of immunoreactivity, affinity, immunohistochemistry, and biodistribution in xenograft model were carried out on ST2485. Analysis of the ST2485 and ST2146 combination was preliminary carried out by ELISA and BiaCore tests and then by in vivo distribution studies after administration of the radiolabeled biotinylated antibodies, followed by a chase with avidin as clearing agent. Results: ST2485 was found to be a suitable antibody for therapeutic applications. Indeed, for its behavior in all tests, it was comparable with ST2146 and better than BC2, an antibody already used for clinical trials. The additivity of ST2146 and ST2485 in tenascin C binding, shown by in vitro tests, was confirmed by biodistribution studies in a xenograft model where tumor localization of the antibodies was near the sum of each antibody alone, with a tumor-to-blood ratio higher than 24. Conclusion: The results reported in this study suggest that a monoclonal antitenascin antibody mixture can improve tumor targeting. This strategy could represent progress for therapeutic approaches such as PAGRIT.

UR - http://www.scopus.com/inward/record.url?scp=26444495000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444495000&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-1004-0007

DO - 10.1158/1078-0432.CCR-1004-0007

M3 - Article

C2 - 16203813

AN - SCOPUS:26444495000

VL - 11

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19 II

ER -